Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (26)

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  2. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400

2022

  1. Role of germline variants in the metastasis of breast carcinomas

    Oncotarget, Vol. 13, Núm. 1, pp. 843-862

2020

  1. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213

  2. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  2. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

  2. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90

  3. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

2017

  1. Physical activity and breast cancer risk by pathological subtype

    Gynecologic Oncology, Vol. 144, Núm. 3, pp. 577-585

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

  2. Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study

    PLoS ONE, Vol. 10, Núm. 5

  3. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis

    Oncologist, Vol. 20, Núm. 2, pp. 111-112

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

  2. Zoledronic acid in the treatment of metastatic breast cancer

    Anti-Cancer Drugs, Vol. 25, Núm. 1, pp. 1-7

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

  2. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis

    Breast Cancer Research, Vol. 15, Núm. 6

2012

  1. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

    Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210